Gaetano De Siena

Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation

&NA; Platinum‐based anticancer drugs cause neurotoxicity. In particular, oxaliplatin produces early‐developing, painful, and cold‐exacerbated paresthesias. However, the mechanism underlying these bothersome and dose‐limiting adverse effects is unknown. We hypothesized that the transient receptor potential ankyrin 1 (TRPA1), a cation channel activated by oxidative stress and cold temperature, contributes to mechanical and cold hypersensitivity caused by oxaliplatin and cisplatin. Oxaliplatin and cisplatin evoked glutathione‐sensitive relaxation, mediated by TRPA1 stimulation and the release of calcitonin gene‐related peptide from sensory nerve terminals in isolated guinea pig pulmonary arteries. No calcium response was observed in cultured mouse dorsal root ganglion neurons or in naïve Chinese hamster ovary (CHO) cells exposed to oxaliplatin or cisplatin. However, oxaliplatin, and with lower potency, cisplatin, evoked a glutathione‐sensitive calcium response in CHO cells expressing mouse TRPA1. One single administration of oxaliplatin produced mechanical and cold hyperalgesia in rats, an effect selectively abated by the TRPA1 antagonist HC‐030031. Oxaliplatin administration caused mechanical and cold allodynia in mice. Both responses were absent in TRPA1‐deficient mice. Administration of cisplatin evoked mechanical allodynia, an effect that was reduced in TRPA1‐deficient mice. TRPA1 is therefore required for oxaliplatin‐evoked mechanical and cold hypersensitivity, and contributes to cisplatin‐evoked mechanical allodynia. Channel activation is most likely caused by glutathione‐sensitive molecules, including reactive oxygen species and their byproducts, which are generated after tissue exposure to platinum‐based drugs from cells surrounding nociceptive nerve terminals. TRPA1 is necessary and sufficient for mechanical‐ and cold‐hypersensitivity evoked by oxaliplatin/cisplatin. TRPA1 activation occurs through reactive molecules, after tissue exposure to platinum‐based drugs.

3‐Iodothyronamine: a modulator of the hypothalamus‐pancreas‐thyroid axes in mice

BACKGROUND AND PURPOSE Preclinical pharmacology of 3‐iodothyronamine (T1AM), an endogenous derivative of thyroid hormones, indicates that it is a rapid modulator of rodent metabolism and behaviour. Since T1AM undergoes rapid enzymatic degradation, particularly by MAO, we hypothesized that the effects of T1AM might be altered by inhibition of MAO.

Parthenolide inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel.

Summary Parthenolide, a major constituent of feverfew, acts as a partial agonist of TRPA1. Parthenolide’s ability to target TRPA1 could explain its therapeutic effects on migraine. Abstract Although feverfew has been used for centuries to treat pain and headaches and is recommended for migraine treatment, the mechanism for its protective action remains unknown. Migraine is triggered by calcitonin gene‐related peptide (CGRP) release from trigeminal neurons. Peptidergic sensory neurons express a series of transient receptor potential (TRP) channels, including the ankyrin 1 (TRPA1) channel. Recent findings have identified agents either inhaled from the environment or produced endogenously that are known to trigger migraine or cluster headache attacks, such as TRPA1 simulants. A major constituent of feverfew, parthenolide, may interact with TRPA1 nucleophilic sites, suggesting that feverfew’s antimigraine effect derives from its ability to target TRPA1. We found that parthenolide stimulates recombinant (transfected cells) or natively expressed (rat/mouse trigeminal neurons) TRPA1, where it, however, behaves as a partial agonist. Furthermore, in rodents, after initial stimulation, parthenolide desensitizes the TRPA1 channel and renders peptidergic TRPA1‐expressing nerve terminals unresponsive to any stimulus. This effect of parthenolide abrogates nociceptive responses evoked by stimulation of peripheral trigeminal endings. TRPA1 targeting and neuronal desensitization by parthenolide inhibits CGRP release from trigeminal neurons and CGRP‐mediated meningeal vasodilatation, evoked by either TRPA1 agonists or other unspecific stimuli. TRPA1 partial agonism, together with desensitization and nociceptor defunctionalization, ultimately resulting in inhibition of CGRP release within the trigeminovascular system, may contribute to the antimigraine effect of parthenolide.

Pharmacological effects of 3‐iodothyronamine (T1AM) in mice include facilitation of memory acquisition and retention and reduction of pain threshold

3‐Iodothyronamine (T1AM), an endogenous derivative of thyroid hormones, is regarded as a rapid modulator of behaviour and metabolism. To determine whether brain thyroid hormone levels contribute to these effects, we investigated the effect of central administration of T1AM on learning and pain threshold of mice either untreated or pretreated with clorgyline (2.5 mg·kg−1, i.p.), an inhibitor of amine oxidative metabolism.

Histamine mediates behavioural and metabolic effects of 3-iodothyroacetic acid, an endogenous end product of thyroid hormone metabolism

3‐Iodothyroacetic acid (TA1) is an end product of thyroid hormone metabolism. So far, it is not known if TA1 is present in mouse brain and if it has any pharmacological effects.

TRPA1 mediates trigeminal neuropathic pain in mice downstream of monocytes/macrophages and oxidative stress

Despite intense investigation, the mechanisms of the different forms of trigeminal neuropathic pain remain substantially unidentified. The transient receptor potential ankyrin 1 channel (encoded by TRPA1) has been reported to contribute to allodynia or hyperalgesia in some neuropathic pain models, including those produced by sciatic nerve constriction. However, the role of TRPA1 and the processes that cause trigeminal pain-like behaviours from nerve insult are poorly understood. The role of TRPA1, monocytes and macrophages, and oxidative stress in pain-like behaviour evoked by the constriction of the infraorbital nerve in mice were explored. C57BL/6 and wild-type (Trpa1(+/+)) mice that underwent constriction of the infraorbital nerve exhibited prolonged (20 days) non-evoked nociceptive behaviour and mechanical, cold and chemical hypersensitivity in comparison to sham-operated mice (P < 0.05-P < 0.001). Both genetic deletion of Trpa1 (Trpa1(-/-)) and pharmacological blockade (HC-030031 and A-967079) abrogated pain-like behaviours (both P < 0.001), which were abated by the antioxidant, α-lipoic acid, and the nicotinamide adenine dinucleotide phosphate oxidase inhibitor, apocynin (both P < 0.001). Nociception and hypersensitivity evoked by constriction of the infraorbital nerve was associated with intra- and perineural monocytic and macrophagic invasion and increased levels of oxidative stress by-products (hydrogen peroxide and 4-hydroxynonenal). Attenuation of monocyte/macrophage increase by systemic treatment with an antibody against the monocyte chemoattractant chemokine (C-C motif) ligand 2 (CCL2) or the macrophage-depleting agent, clodronate (both P < 0.05), was associated with reduced hydrogen peroxide and 4-hydroxynonenal perineural levels and pain-like behaviours (all P < 0.01), which were abated by perineural administration of HC-030031, α-lipoic acid or the anti-CCL2 antibody (all P < 0.001). The present findings propose that, in the constriction of the infraorbital nerve model of trigeminal neuropathic pain, pain-like behaviours are entirely mediated by the TRPA1 channel, targeted by increased oxidative stress by-products released from monocytes and macrophages clumping at the site of nerve injury.

In the brain of mice, 3-iodothyronamine (T1AM) is converted into 3-iodothyroacetic acid (TA1) and it is included within the signaling network connecting thyroid hormone metabolites with histamine.

3-iodothyronamine (T1AM) and its oxidative product, 3-iodotyhyroacetic acid (TTA1A), are known to stimulate learning and induce hyperalgesia in mice. We investigated whether i)TA1 may be generated in vivo from T1AM, ii) T1AM shares with TA1 the ability to activate the histaminergic system. Tandem mass spectrometry was used to measure TA1 and T1AM levels in i) the brain of mice following intracerebroventricular (i.c.v.) injection of T1AM (11μgkg(-1)), with or without pretreatment with clorgyline, (2.5mgkg(-1) i.p.), a monoamine oxidase inhibitor; ii) the medium of organotypic hippocampal slices exposed to T1AM (50nM). In addition, learning and pain threshold were evaluated by the light-dark box task and the hot plate test, respectively, in mice pre-treated subcutaneously with pyrilamine (10mgkg(-1)) or zolantidine (5mgkg(-1)), 20min before i.c.v. injection of T1AM (1.32 and 11μgkg(-1)). T1AM-induced hyperalgesia (1.32 and 11μgkg(-1)) was also evaluated in histidine decarboxylase (HDC(-/-)) mice. T1AM and TA1 brain levels increased in parallel in mice injected with T1AM with the TA1/T1AM averaging 1.7%. Clorgyline pre-treatment reduced the increase in both T1AM and TA1. TA1 was the main T1AM metabolite detected in the hippocampal preparations. Pretreatment with pyrilamine or zolantidine prevented the pro-learning effect of 1.32 and 4μgkg(-1) T1AM while hyperalgesia was conserved at the dose of 11μgkg(-1) T1AM. T1AM failed to induce hyperalgesia in HDC(-/-) mice at all the doses. In conclusion, TA1 generated from T1AM, but also T1AM, appears to act by modulating the histaminergic system.

3‐iodothyroacetic acid, a metabolite of thyroid hormone, induces itch and reduces threshold to noxious and to painful heat stimuli in mice

Itch is associated with increased sensitization to nociceptive stimuli. We investigated whether 3‐iodothyroacetic acid (TA1), by releasing histamine, induces itch and increases sensitization to noxious and painful heat stimuli.

Blue led treatment of superficial abrasions

A compact and easy-to-handle photocoagulation device was used for inducing an immediate coagulation effect in skin large superficial abrasions, reducing the recovering time and improving the wound healing process. The handheld illumination device consists of a high power LED, emitting in the blue region of the spectrum, mounted in a suitable and ergonomic case, together with power supply, electronics, and batteries. The working principle of the LED-based photocoagulator is a photothermal effect: the blue light is selectively absorbed by the haemoglobin content of the blood and then converted into heat. Here we present an in vivo study performed on animal models. 10 Sprague Dawley rats (Harlan, Italy, weighing 200-250 g) were used to study the wound healing process. On the back of each rat, four large abrasions were mechanically produced: two of them were used as a control, while the other two were treated with the photocoagulator, keeping it at a constant distance (2 mm) from the target, in continuous slow motion (treatment time: tens of seconds). The induced photothermal effect was monitored by an infrared thermocamera in order to avoid accidental thermal damage and to control the temperature dynamics during treatment. Objective observations, histopathological analysis and non-linear microscopy performed in a 8 days follow-up study showed no adverse reactions and no thermal damage in the treated areas and surrounding tissues. Moreover, a faster healing process and a better recovered morphology was evidenced in the treated tissue.

The impact of scopolamine pretreatment on 3-iodothyronamine (T1AM) effects on memory and pain in mice☆

ABSTRACT We previously demonstrated that 3‐iodothyronamine (T1AM), a by‐product of thyroid hormone metabolism, pharmacologically administered to mice acutely stimulated learning and memory acquisition and provided hyperalgesia with a mechanism which remains to be defined. We now aimed to investigate whether the T1AM effect on memory and pain was maintained in mice pre‐treated with scopolamine, a non‐selective muscarinic antagonist expected to induce amnesia and, possibly, hyperalgesia. Mice were pre‐treated with scopolamine and, after 20 min, injected intracerebroventricularly (i.c.v.) with T1AM (0.13, 0.4, 1.32 &mgr;g/kg). 15 min after T1AM injection, the mice learning capacity or their pain threshold were evaluated by the light/dark box and by the hot plate test (51.5 °C) respectively. Experiments in the light/dark box were repeated in mice receiving clorgyline (2.5 mg/kg, i.p.), a monoamine oxidase (MAO) inhibitor administered 10 min before scopolamine (0.3 mg/kg). Our results demonstrated that 0.3 mg/kg scopolamine induced amnesia without modifying the murine pain threshold. T1AM fully reversed scopolamine‐induced amnesia and produced hyperalgesia at a dose as low as 0.13 &mgr;g/kg. The T1AM anti‐amnestic effect was lost in mice pre‐treated with clorgyline. We report that the removal of muscarinic signalling increases T1AM pro learning and hyperalgesic effectiveness suggesting T1AM as a potential treatment as a “pro‐drug” for memory dysfunction in neurodegenerative diseases. HIGHLIGHTST1AM fully reverts scopolamine‐induced amnesia.T1AM effectiveness on memory and pain increases in the presence of scopolamine.T1AM as a pro‐drug for treating memory disorders associated with altered pain perception.